Misplaced Pages

Dazoxiben

Names
Preferred IUPAC name 4-benzoic acid
Identifiers
CAS Number	78218-09-4
3D model (JSmol)	Interactive image
ChEMBL	ChEMBL267473
ChemSpider	47885
DrugBank	DB03052
IUPHAR/BPS	5175
PubChem CID	53001
UNII	09ZFC7974Q
CompTox Dashboard (EPA)	DTXSID9045639
InChI InChI=1S/C12H12N2O3/c15-12(16)10-1-3-11(4-2-10)17-8-7-14-6-5-13-9-14/h1-6,9H,7-8H2,(H,15,16)Key: XQGZSYKGWHUSDH-UHFFFAOYSA-N InChI=1/C12H12N2O3/c15-12(16)10-1-3-11(4-2-10)17-8-7-14-6-5-13-9-14/h1-6,9H,7-8H2,(H,15,16)Key: XQGZSYKGWHUSDH-UHFFFAOYAY
SMILES O=C(O)c2ccc(OCCn1ccnc1)cc2
Properties
Chemical formula	C12H12N2O3
Molar mass	232.239 g·mol
Except where otherwise noted, data are given for materials in their standard state (at 25 °C , 100 kPa). N verify (what is  ?) Infobox references

Dazoxiben is an orally active thromboxane synthase inhibitor. It has shown a significant clinical improvement in patients with Raynaud's syndrome.

Synthesis

One convenient synthesis starts with the O-chloroethyl ether of p-hydroxybenzamide and proceeds bydisplacement with imidazole to give 2. Hydrolysis of the amide function completes the synthesis of dazoxiben.

References

1. Belch, J. J.; Cormie, J.; Newman, P.; McLaren, M.; Barbenel, J.; Capell, H.; Leiberman, P.; Forbes, C. D.; Prentice, C. R. (1983). "Dazoxiben, a thromboxane synthetase inhibitor, in the treatment of Raynaud's syndrome: A double-blind trial". British Journal of Clinical Pharmacology. 15 Suppl 1 (Suppl 1): 113S – 116S. doi:10.1111/j.1365-2125.1983.tb02119.x. PMC 1427695. PMID 6337601.
2. Belch, J. J.; Cormie, J.; Newman, P.; McLaren, M.; Barbenel, J.; Capell, H.; Leiberman, P.; Forbes, C. D.; Prentice, C. R. (1983). "Dazoxiben, a thromboxane synthetase inhibitor, in the treatment of Raynaud's syndrome: A double-blind trial". British Journal of Clinical Pharmacology. 15 Suppl 1 (Suppl 1): 113S – 116S. doi:10.1111/j.1365-2125.1983.tb02119.x. PMC 1427695. PMID 6337601.
3. DE 2950019, Cross, Peter Edward & Dickinson, Roger Peter, "Imidazolderivate, Verfahren zu ihrer Herstellung und diese enthaltende Arzneimittel ", published 1980-07-10, assigned to Pfizer Corp. 
4. Kochergin, P. M.; Palei, R. M.; Balandina, L. V.; Kharitonova, A. E.; Kravchenko, A. N.; Persanova, L. V.; Govorukhina, E. I.; Frolova, M. A. (1995). "Simplified synthesis of dazoxiben". Pharmaceutical Chemistry Journal. 29 (2): 139. doi:10.1007/BF02226528. S2CID 37387182.
5. Iizuka, Kinji; Akahane, Kenji; Momose, Denichi; Nakazawa, Masayuki; Tanouchi, Tadao; Kawamura, Masanori; Ohyama, Isao; Kajiwara, Ikuo; Iguchi, Yohichi (1981). "Highly selective inhibitors of thromboxane synthetase. 1. Imidazole derivatives". Journal of Medicinal Chemistry. 24 (10): 1139–1148. doi:10.1021/jm00142a005. PMID 7199088.
6. Cross, Peter E.; Dickinson, Roger P.; Parry, M. John; Randall, Michael J. (1985). "Selective thromboxane synthetase inhibitors. 1. 1--1H-imidazoles". Journal of Medicinal Chemistry. 28 (10): 1427–1432. doi:10.1021/jm00148a009. PMID 3930740.

This drug article relating to the blood and blood forming organs is a stub. You can help Misplaced Pages by expanding it.

• v
• t
• e

• Antithrombotic agents
• Imidazoles
• Benzoic acids
• Ethanolamines
• Blood and blood forming organ drug stubs